Recombinant antibody Fragment Fab to TNF alpha. Certolizumab pegol is a monoclonal antibody directed against tumor necrosis factor alpha. More precisely, it is a PEGylated Fab' fragment of a humanized TNF inhibitor monoclonal antibody. Polyethylene glycol does not cross the placenta, so it should be safe in pregnancy.
Figure 1 Efficacy variables in the certolizumab pegol (CZP) intention-to-treat (ITT) (n = 492) and week-24 CZP completer populations (n = 342).
a Mean disease activity score in 28 joints (erythrocyte sedimentation rate) (DAS28(ESR)). b Mean health assessment questionnaire-disability index (HAQ-DI). c American College of Rheumatologists (ACR)20 response. d ACR50 and ACR70 responses. For patients who withdrew at week 16, observed data from the week-12 visit was also included in the week-24 data (start of open-label extension). MMRM mixed model repeated measures, NRI non-responder imputation.
Smolen, J. S., van Vollenhoven, R., Kavanaugh, A., Strand, V., Vencovsky, J., Schiff, M.,... & Carter, D. (2015). Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. Arthritis research & therapy, 17(1), 245.
Figure 2 Efficacy variables in patients following dose reduction from certolizumab pegol (CZP) 400 mg every 2 weeks (Q2W) to CZP 200 mg Q2W (n = 369).
a Mean disease activity score in 8 joints (erythrocyte sedimentation rate) (DAS28(ESR)). bAmerican College of Rheumatology (ACR)20 response rates. c ACR50 and ACR70 response rates. This analysis is presented as weeks following dose-reduction visit (Week 0 is defined as the final efficacy assessment visit where a patient received the CZP 400 mg dose).
Smolen, J. S., van Vollenhoven, R., Kavanaugh, A., Strand, V., Vencovsky, J., Schiff, M.,... & Carter, D. (2015). Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. Arthritis research & therapy, 17(1), 245.
Figure 3 Effect of CZP in patients with and without prior TNF inhibitor exposure at week 24 in terms of ACR response and the kinetics of ACR response.
CZP, Certolizumab pegol; Q2W, every 2 weeks; Q4W, every 4 weeks; PBO, placebo; TNF, tumour necrosis factor. (A) Percentages of patients with and without prior TNF inhibitor exposure achieving a response according to the American College of Rheumatology Criteria for 20% improvement (ACR20), 50% improvement (ACR50), and 70% improvement (ACR70) at week 24, by treatment group. (B) Percentages of patients with prior TNF inhibitor exposure achieving an ACR20, ACR50, and ACR70 response over time, by treatment group. (C) Percentages of patients without prior TNF inhibitor exposure achieving an ACR20, ACR50 and ACR70 response over time, by treatment group; *p<0.001; †p<0.05 versus placebo.
Mease, P. J., Fleischmann, R., Deodhar, A. A., Wollenhaupt, J., Khraishi, M., Kielar, D.,... & Van Der Heijde, D. (2014). Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Annals of the rheumatic diseases, 73(1), 48-55.
Figure 4 Emotional Function and Systemic Symptoms were the domains that patients reported as being most improved by certolizumab pegol treatment.
Mean change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) domain scores during 12 weeks subcutaneous treatment with either certolizumab pegol or placebo in patients with moderate-to-severe Crohn's disease (intent-to-treat population); least-squares means (adjusted for stratum, pooled country, and baseline score): a Bowel Symptoms domain, b Systemic Symptoms domain, c Emotional Function domain, and d Social Function domain.
Rutgeerts, P., Schreiber, S., Feagan, B., Keininger, D. L., O’Neil, L., & Fedorak, R. N. (2008). Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFα, improves health-related quality of life in patients with moderate to severe Crohn’s disease. International journal of colorectal disease, 23(3), 289-296.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-768 | Anti-TNF alpha Recombinant Antibody (Nerelimomab) | FuncS, IF, Neut, ELISA, FC, IP, ICC | IgG1 |
TAB-123CQ-S(P) | Mouse Anti-TNF Recombinant Antibody; scFv Fragment (TAB-123CQ-S(P)) | ELISA, Neut | Mouse scFv |
TAB-130CQ-S(P) | Anti-Human TNF Recombinant Antibody scFv Fragment (m357) | ELISA, FC, Neut | |
TAB-132CQ-S(P) | Anti-Human TNF Recombinant Antibody scFv Fragment (MAK195) | ELISA, Neut | |
TAB-139CQ-S(P) | Rabbit Anti-TNF Recombinant Antibody; scFv Fragment (TAB-139CQ-S(P)) | ELISA, FC, IF | Rabbit scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-254 | Anti-Human TNF Recombinant Antibody (Placulumab) | Neut, ELISA, IF, IP, FuncS, FC, ICC | [V-kappa]2 - Fc |
TAB-111CQ-S(P) | Anti-Human TNF Recombinant Antibody scFv Fragment (B5) | ELISA, WB | Human antibody |
TAB-113CQ-S(P) | Human Anti-TNF Recombinant Antibody; scFv Fragment (TAB-113CQ-S(P)) | ELISA | Human scFv |
TAB-119CQ-F(E) | Human Anti-TNF Recombinant Antibody; Fab Fragment (TAB-119CQ-F(E)) | ELISA, BL | Human Fab |
TAB-120CQ-F(E) | Anti-Human TNF Recombinant Antibody Fab Fragment (IB-SA2n) | ELISA, Neut | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-623CL | Bovine Anti-TNF Recombinant Antibody (TAB-623CL) | Neut | Bovine IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
PFBL-349 | Human Anti-TNF Recombinant Antibody (clone A2); Fab Fragment | WB, ELISA, FuncS | Human Fab |
HPAB-0046-FY-F(E) | Mouse Anti-TNF Recombinant Antibody (clone 1B7); Fab Fragment | Neut | Mouse Fab |
HPAB-0675-CN-F(E) | Human Anti-TNF Recombinant Antibody; Fab Fragment (HPAB-0675-CN-F(E)) | ELISA, Neut | Humanized Fab |
HPAB-0676-CN-F(E) | Human Anti-TNF Recombinant Antibody; Fab Fragment (HPAB-0676-CN-F(E)) | ELISA, Neut | Humanized Fab |
HPAB-0303-WJ-F(E) | Human Anti-TNF Recombinant Antibody (clone BPC1500); Fab Fragment | ELISA | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-124CQ | Human Anti-TNF Recombinant Antibody (TAB-124CQ) | FuncS, Neut | Humanized antibody |
TAB-125CQ | Human Anti-TNF Recombinant Antibody (TAB-125CQ) | ELISA, Neut | Humanized antibody |
TAB-126CQ | Human Anti-TNF Recombinant Antibody (TAB-126CQ) | ELISA, Neut | Humanized antibody |
TAB-127CQ | Human Anti-TNF Recombinant Antibody (TAB-127CQ) | ELISA, Neut | Humanized antibody |
TAB-128CQ | Human Anti-TNF Recombinant Antibody (TAB-128CQ) | ELISA, FuncS | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-148CQ | Anti-Human TNF Recombinant Antibody | ELISA | Chimeric antibody (mouse/human) |
TAB-402CQ | Human Anti-TNF Recombinant Antibody (TAB-402CQ) | ELISA | Chimeric (mouse/human) IgG |
TAB-148CQ-S(P) | Anti-Human TNF Recombinant Antibody scFv Fragment | ELISA | Chimeric antibody (mouse/human) |
TAB-148CQ-F(E) | Anti-Human TNF Recombinant Antibody Fab Fragment | ELISA | Chimeric antibody (mouse/human) |
TAB-402CQ-F(E) | Human Anti-TNF Recombinant Antibody; Fab Fragment (TAB-402CQ-F(E)) | ELISA | Chimeric (mouse/human) Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-412CQ | Anti-Human TNF Therapeutic Single Domain Antibody (TAR1-5-19) | ELISA, Inhib | Single domain antibody |
TAB-413CQ | Anti-Human TNF Therapeutic Single Domain Antibody (VL18) | ELISA, WB, Neut | Single domain antibody |
TAB-414CQ | Anti-Human TNF Therapeutic Single Domain Antibody (VL11) | ELISA, WB, Neut | Single domain antibody |
TAB-415CQ | Anti-Human TNF Therapeutic Single Domain Antibody (VL18-3L-VL11) | ELISA, WB, Neut, FunS | Single domain antibody |
HPAB-M0402-YC | Recombinant Chiloscyllium shark Anti-TNF Single Domain Antibody (3D2) | ELISA | Chiloscyllium shark vNAR single domain antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-083LC | Recombinant Anti-Human TNF Antibody (Fc glycosylation/Non-hyper galactosylated) | ELISA, FC | Human antibody |
Gly-085LC | Recombinant Anti-Human TNF Antibody (Fc glycosylation/Sialylated) | ELISA, FC | Human antibody |
Gly-086LC | Recombinant Anti-Human TNF Antibody (Fc glycosylation/Hyper-galactosylated) | ELISA, FC | Human antibody |
Gly-087LC | Recombinant Anti-Human TNF Antibody (Fc glycosylation/Hyper-galactosylated) | ELISA, FC | Human antibody |
Gly-163LC | Recombinant Anti-Human TNF Antibody (Fc glycosylation/Sialylated) | ELISA | Chimeric antibody (mouse/human) |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-083LC-1 | Recombinant Anti-Human TNF Antibody (Fc glycosylation/Non-hyper galactosylated) | ELISA, FC | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-085LC-1 | Recombinant Anti-Human TNF Antibody (Fc glycosylation/Sialylated) | ELISA, FC | Human antibody |
Gly-163LC-1 | Recombinant Anti-Human TNF Antibody (Fc glycosylation/Sialylated) | ELISA | Chimeric antibody (mouse/human) |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-086LC-1 | Recombinant Anti-Human TNF Antibody (Fc glycosylation/Hyper-galactosylated) | ELISA, FC | Human antibody |
Gly-087LC-1 | Recombinant Anti-Human TNF Antibody (Fc glycosylation/Hyper-galactosylated) | ELISA, FC | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-0229MZ | Recombinant Mouse Anti-Human TNF Antibody (clone G7C6) | ELISA, IHC | Mouse antibody |
HPAB-0007-YC | Human Anti-TNF Recombinant Antibody (clone cA2) | ELISA, Neut | Chimeric (mouse/human) IgG1 |
HPAB-0557LY | Human Anti-TNF Recombinant Antibody (clone CBL013LY) | ELISA | Human IgG1 |
HPAB-0332-YJ | Mouse Anti-TNF Recombinant Antibody (HPAB-0332-YJ) | ELISA, FuncS | Mouse IgG |
HPAB-1433-FY | Human Anti-TNF Recombinant Antibody (clone 121E1B) | ELISA | Human IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
BRD-0609MZ | Chicken Anti-Tumor Necrosis Factor-α Polyclonal IgY | Indirect ELISA, WB | Chicken antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-2051CQ | Mouse Anti-TNF Recombinant Antibody (clone CBL589) | ELISA, ICC, Neut | Mouse IgG1 |
NEUT-2052CQ | Mouse Anti-TNF Recombinant Antibody (clone CBL570) | WB, Neut | Mouse IgG2b |
NEUT-2053CQ | Mouse Anti-TNF Recombinant Antibody (clone CBL571) | WB, Neut | Mouse IgG1 |
NEUT-2054CQ | Rat Anti-Tnf Recombinant Antibody (clone mAb0856) | Neut | Rat IgG1 |
NEUT-2108CQ | Mouse Anti-TNF Recombinant Antibody (clone mAb11) | ELISA, CyTOF, FC, ICFC, ICC, IF, IHC, Neut | Mouse IgG1, κ |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-2057CQ | Rat Anti-Tnf Recombinant Antibody (clone XT3) | Block, ELISA, IHC, WB | Rat IgG1 |
NEUT-2070CQ | Mouse Anti-TNF Recombinant Antibody (clone 4F4) | Block, ELISA, ICC, IF, IHC, WB | Mouse IgG1 |
NEUT-2071CQ | Rabbit Anti-TNF Recombinant Antibody (clone 6E10) | Block, ELISA, IHC, WB | Rabbit IgG1 |
NEUT-2082CQ | Mouse Anti-TNF Recombinant Antibody (clone B-C7) | Block | Mouse IgG1 |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-4460 | Rabbit Anti-TNF Recombinant Antibody (clone SI554DS) | ELISA | Rabbit IgG |
MOR-4461 | Rabbit Anti-TNF Recombinant Antibody (clone SI555DS) | Neut | Rabbit IgG |
MOR-4462 | Rabbit Anti-TNF Recombinant Antibody (clone SI556DS) | FC | Rabbit IgG |
MOR-4463 | Rabbit Anti-TNF Recombinant Antibody (clone SI557DS) | FC | Rabbit IgG |
MOR-4464 | Rabbit Anti-TNF Recombinant Antibody (clone SI558DS) | FC | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0151-YC-S(P) | Human Anti-TNF Recombinant Antibody; scFv Fragment (HPAB-0151-YC-S(P)) | ELISA, Inhib, FuncS | Human scFv |
HPAB-0513-WJ-S(P) | Human Anti-TNF Recombinant Antibody; scFv Fragment (HPAB-0513-WJ-S(P)) | ELISA | Human scFv |
HPAB-1808-FY-F(E) | Human Anti-TNF Recombinant Antibody (clone AB197); scFv Fragment | Neut | Human scFv |
HPAB-2087-FY-S(P) | Mouse Anti-TNF Recombinant Antibody (clone CB0010); scFv Fragment | Neut | Mouse scFv |
HPAB-1564WJ-S(P) | Mouse Anti-TNF Recombinant Antibody; scFv Fragment (clone 3B10) | ELISA, WB, Neut | Mouse scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-768 | Afuco™ Anti-TNF ADCC Recombinant Antibody (Nerelimomab), ADCC Enhanced | FuncS, IF, Neut, ELISA, FC, IP | ADCC enhanced antibody |
AFC-TAB-006 | Afuco™ Anti-TNF ADCC Recombinant Antibody (Infliximab), ADCC Enhanced | IF, IP, Neut, FuncS, ELISA, FC | ADCC enhanced antibody |
AFC-TAB-010 | Afuco™ Anti-TNF ADCC Recombinant Antibody (AFC-TAB-010), ADCC Enhanced | FC, IP, ELISA, Neut, FuncS | ADCC enhanced antibody |
There are currently no Customer reviews or questions for TAB-034-F(E). Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.